Paul Tudor Jones's PTCT Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 7,412 shares of PTC Therapeutics, Inc. (PTCT) worth $563,016, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 37 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in PTCT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2016, adding 83,427 shares. Largest reduction occurred in Q4 2021, reducing 104,734 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +7,412 | New Buy | 7,412 | $75.96 |
| Q2 2025 | -40,112 | Sold Out | 0 | $0.00 |
| Q1 2025 | -7,039 | Reduce 14.93% | 40,112 | $50.96 |
| Q4 2024 | +8,505 | Add 22.01% | 47,151 | $45.14 |
| Q3 2024 | -14,515 | Reduce 27.30% | 38,646 | $37.10 |
| Q2 2024 | +24,687 | Add 86.70% | 53,161 | $30.58 |
| Q1 2024 | -21,081 | Reduce 42.54% | 28,474 | $29.09 |
| Q4 2023 | +49,555 | New Buy | 49,555 | $27.56 |
| Q4 2022 | -8,626 | Sold Out | 0 | $0.00 |
| Q3 2022 | -8,257 | Reduce 48.91% | 8,626 | $50.20 |
| Q2 2022 | +3,041 | Add 21.97% | 16,883 | $40.04 |
| Q1 2022 | +3,669 | Add 36.07% | 13,842 | $37.28 |
| Q4 2021 | -104,734 | Reduce 91.15% | 10,173 | $39.81 |
| Q3 2021 | +24,666 | Add 27.33% | 114,907 | $37.21 |
| Q2 2021 | +53,087 | Add 142.88% | 90,241 | $42.26 |
| Q1 2021 | +17,697 | Add 90.95% | 37,154 | $47.34 |
| Q4 2020 | +19,457 | New Buy | 19,457 | $61.01 |
| Q4 2019 | -8,037 | Sold Out | 0 | $0.00 |
| Q3 2019 | +8,037 | New Buy | 8,037 | $33.84 |
| Q2 2019 | -10,612 | Sold Out | 0 | $0.00 |
| Q1 2019 | -8,738 | Reduce 45.16% | 10,612 | $37.60 |
| Q4 2018 | +8,352 | Add 75.94% | 19,350 | $34.32 |
| Q3 2018 | +10,998 | New Buy | 10,998 | $47.01 |
| Q1 2018 | -27,031 | Sold Out | 0 | $0.00 |
| Q4 2017 | +7,761 | Add 40.28% | 27,031 | $16.68 |
| Q3 2017 | +19,270 | New Buy | 19,270 | $20.03 |
| Q2 2017 | -41,670 | Sold Out | 0 | $0.00 |
| Q1 2017 | +41,670 | New Buy | 41,670 | $9.84 |
| Q3 2016 | -10,500 | Sold Out | 0 | $0.00 |
| Q2 2016 | -72,927 | Reduce 87.41% | 10,500 | $7.05 |
| Q1 2016 | +83,427 | New Buy | 83,427 | $6.44 |
| Q4 2015 | -9,400 | Sold Out | 0 | $0.00 |
| Q3 2015 | -400 | Reduce 4.08% | 9,400 | $26.70 |
| Q2 2015 | +6,486 | Add 195.72% | 9,800 | $48.16 |
| Q1 2015 | -5,563 | Reduce 62.67% | 3,314 | $60.95 |
| Q4 2014 | +4,166 | Add 88.43% | 8,877 | $51.82 |
| Q3 2014 | +4,711 | New Buy | 4,711 | $43.94 |
Paul Tudor Jones's PTC Therapeutics Investment FAQs
Paul Tudor Jones first purchased PTC Therapeutics, Inc. (PTCT) in Q3 2014, acquiring 4,711 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held PTC Therapeutics, Inc. (PTCT) for 37 quarters since Q3 2014.
Paul Tudor Jones's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q1 2016, adding 83,427 shares worth $537,000.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 7,412 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $563,016.
As of the Q4 2025 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in PTC Therapeutics, Inc. (PTCT) was 114,907 shares, as reported at the end of Q3 2021.